Latest news

BIO International Convention

Mon - 06, 06/03 - 06/2019 - 08:00

Do not hesitate to contact us if you want to meet our team during BIO International Convention 201

Read more

ELSALYS BIOTECH has benefited from the support of the Auvergne Rhône Alpes Region

Wed, 05/08/2019 - 08:00

In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium o

Read more

BioWorld - Elsalys looks to cross goal line in SR-aGVHD on positive long-term OS

Mon, 02/18/2019 - 08:46 - Tue, 02/01/2022 - 09:00

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

Read more

Long-term survival analysis of the randomised Phase III study shows a clear clinical benefit of inolimomab in SR-aGvHD

Wed, 01/23/2019 - 14:00 - Wed, 02/23/2022 - 14:00
    Read more

    Elsalys Biotech participates in JP Morgan Healthcare Conference

    Mon - 10, 01/07 - 10/2019 - 08:00

    Visit JP Morgan's Website

    Read more

    1st edition of the Days of the "antibody CLub" of the French Society of Immunology

    Thu - 09, 11/08 - 09/2018 - 08:30

    Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin

    Read more

    ElsaLys Biotech at BIO-Europe 2018

    Mon - 07, 11/05 - 07/2018 - 09:00

    Do not hesitate to contact us if you want to meet our team during Bio-Eu

    Read more

    New studies confirm anti-CD160 antibodies are potential therapeutics for ophthalmic diseases

    Mon, 07/02/2018 - 15:00 - Fri, 07/02/2021 - 15:30
    • Efficacy and safety are consistently demonstrated in several in vivo preclinical models
    • Anti-CD160 is a potent inhibitor of ocular v
    Read more

    STAY IN TOUCH WITH OUR LATEST NEWS

    Subcribe to our newsletter

    Subscribe now
    Copyright 2018 ElsaLys Biotech SA

    This website uses cookies to track its audience and improve its content.

    By continuing to browse this website, you agree to the use of such cookies.